References
- Pecoraro A, Fishman M, Ma M, Piralishvili G, Woody G. Pharmacologically assisted treatment of opioid-dependent youth. Pediatr Drugs. 2013;15:449–458.
- Woody GE, Poole SA, Subramaniam G, et al. Extended vs. Short-term buprenorphine-Naloxone for treatment of opioid addicted youth. JAMA. 2008;300:2003–2011.
- Subramaniam GA, Stitzer ML, Woody G, Fishman M, Ken K. Clinical characteristics of treatment-seeking adolescents with opioid versus cannabis/alcohol use disorders. Drug Alcohol Depend. 2009;99:141–149.
- Matson SC, Hobson G, Abdel-Rasoul M, Bonny AE. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic. J Addict Med. 2014;8:176–182.
- Pugatch M, Knight JR, McGuiness P, Sherritt L, Levy S. A group therapy program for opioid-dependent adolescents and their parents. Subst Abus. 2014;35:435–441.
- Fishman M, Winstanley E, Curran E, Garrett S, Subramaniam G. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case series and feasibility. Addiction. 2010;105:1669–1676.
- Hulse GK, Tait RJ. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in ‘high-risk’ adolescent heroin users. Addict Biol. 2003;8:337–342.
- Schuman-Olivier Z, Weiss DR, Bettina BH, Borodosvsky J, Albanese JM. Emerging adult age status predicts poor buprenorphine treatment retention. J Subst Abuse Treat. 2014;47:202–212.
- Dreifuss JA, Griffin M, Frost L, et al. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: results from a multisite study. Drug Alcohol Depend. 2013;131:112–118.
- Nunes EV, Krupitsky E, Ling W, et al. Treating opioid dependence with injectable extended-release naltrexone (XR-NTX) who will respond?. J Addict Med. 2015;9:238–243.
- Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063–2066.
- Hser Y, Saxon A, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2013;109:79–87.
- Wu L, Blazer DG, Li T, Woody GW. Treatment use and barriers among adolescents with prescription opioid use disorders: 2005–2008. Addict Behav. 2011;36:1233–1239.
- Gandhi DH, Jaffe JH, McNary S, et al. Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users. Addiction. 2003;98:453–462.
- Warden D, Riggs PD, Sung-Joon M, et al. Major depression and treatment response in adolescents with ADHD and substance use disorder. Drug Alcohol Depend. 2012;120:214–219.
- Subramaniam GA, Ives ML, Stitzer ML, Dennis ML. The added risk of opioid problem use among treatment-seeking youth with marijuana and/or alcohol problem use. Addiction. 2010;105:686–698.